Aldeyra Therapeutics (ALDX) to Present Phase 2 Allergic Conjunctivitis Data at Upcoming Industry Meeting

November 7, 2016 8:04 AM EST

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced an upcoming poster presentation at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting to be held November 10th -14th in San Francisco, CA. The presentation will summarize the results of a Phase 2 clinical trial of ADX-102 topical ophthalmic solution in a challenge model of allergic conjunctivitis in 100 subjects.

Details of the presentation are as follows:

  • Title: A Randomized Double-Masked Phase 2 Clinical Trial of NS2 Ophthalmic Solution in Allergic Conjunctivitis
  • Date: Saturday November 12that 1:00 p.m.
  • Location: Moscone West Convention Center - Monitor No. 8
  • Presented by: David Clark, M.D., M.R.C.P., A.F.P.M, Chief Medical Officer of Aldeyra Therapeutics
  • Poster #: P316

The data represent the first demonstration of the clinical efficacy of aldehyde trapping in human disease, and support the continued development of ADX-102 in allergic conjunctivitis and other inflammatory diseases.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News

Add Your Comment